C. Gori

发表

The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing

F. Ceccherini‐Silberstein, G. Ippolito, M. Capobianchi, 2013, PloS one.

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

A. d’Arminio Monforte, F. Baldanti, F. Ceccherini‐Silberstein, 2012, The new microbiologica.

Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.

P. Narciso, A. Antinori, V. Tozzi, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs

L. Pucillo, A. Antinori, C. Perno, 2014, BMC Medical Genetics.

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, A. Giannetti, 2020, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

F. Ceccherini‐Silberstein, A. Giannetti, A. Antinori, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon

C. Perno, V. Colizzi, C. Perno, 2011, Archives of Virology.

A Very Low Geno2pheno False Positive Rate Is Associated with Poor Viro-Immunological Response in Drug-Naïve Patients Starting a First-Line HAART

V. Calvez, F. Ceccherini‐Silberstein, A. Antinori, 2014, PloS one.

Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs

F. Ceccherini‐Silberstein, M. Ciccozzi, C. Perno, 2009, BMC infectious diseases.

Recent Transmission Clustering of HIV-1 C and CRF17_BF Strains Characterized by NNRTI-Related Mutations among Newly Diagnosed Men in Central Italy

F. Ceccherini‐Silberstein, E. Nicastri, A. Antinori, 2015, PloS one.

Circulation of HIV-1 CRF02_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study

M. Ciccozzi, A. Lo Presti, E. Cella, 2013, BioMed research international.

One-carbon pathway metabolites are altered in the plasma of subjects with Down syndrome: Relation to chromosomal dosage

L. Vitale, A. Piovesan, F. Antonaros, 2021, bioRxiv.

HIV MDR is still a relevant issue despite its dramatic drop over the years.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2020, The Journal of antimicrobial chemotherapy.

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.

F. Ceccherini‐Silberstein, A. Giannetti, A. Antinori, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Using a Database of HIV Patients Undergoing Genotypic Resistance Test after Haart Failure to Understand the Dynamics of M184V Mutation

A. Antinori, V. Tozzi, P. Noto, 2003, Antiviral therapy.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

C. Perno, C. Perno, A. Bertoli, 2011, Antiviral research.

Construction, Training and Clinical Validation of An Interpretation System for Genotypic HIV-1 Drug Resistance Based on Fuzzy Rules Revised by Virological Outcomes

Marilena Vendittelli, Giovanni Ulivi, Francesco Baldini, 2003, Antiviral therapy.

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

F. Ceccherini‐Silberstein, H. Fleury, F. Mazzotta, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.

F. Ceccherini‐Silberstein, C. Perno, A. Spanò, 2009, Journal of hepatology.

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.

F. Ceccherini‐Silberstein, A. Ursitti, C. Perno, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Impact of Pre-Therapy Viral Load on Virological Response to Modern First-Line Haart

F. Ceccherini‐Silberstein, P. Narciso, E. Nicastri, 2013, Antiviral therapy.

Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2012, Antiviral research.

Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2004, AIDS.

Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013–2020

M. Capobianchi, A. Antinori, V. Puro, 2021, Viruses.

High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations

F. Ceccherini‐Silberstein, F. Gago, A. Antinori, 2005, Journal of Virology.

Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors

Valentina Svicher, Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, 2005, Antimicrobial Agents and Chemotherapy.

Molecular diversity of HIV in Albania.

F. Ceccherini‐Silberstein, M. Ciccozzi, G. Rezza, 2005, The Journal of infectious diseases.

Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice

F. Ceccherini‐Silberstein, A. Antinori, M. Zazzi, 2019, Virus Genes.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012, AIDS research and human retroviruses.

Virological and Immunological Outcomes of an Intensified Four-Drug versus a Standard Three-Drug Antiretroviral Regimen, Both Integrase Strand Transfer Inhibitor-Based, in Primary HIV Infection

C. Agrati, M. Capobianchi, A. Antinori, 2022, Pharmaceuticals.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains

Francesco Montella, Claudia Alteri, Vanni Borghi, 2017, Journal of Clinical Microbiology.

An HIV type 2 case series in Italy: a phylogenetic analysis.

B. Foley, G. d’Ettorre, V. Vullo, 2013, AIDS research and human retroviruses.

Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients

P. Narciso, A. Antinori, V. Tozzi, 2005, AIDS.

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

F. Ceccherini‐Silberstein, V. Colizzi, C. Fokunang, 2019, BMC Infectious Diseases.

Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia

F. Ceccherini‐Silberstein, A. Antinori, C. Mussini, 2015, Journal of Clinical Microbiology.

Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels.

F. Ceccherini‐Silberstein, E. Nicastri, A. Antinori, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Fast and sensitive quantitative detection of HIV DNA in whole blood leucocytes by SYBR green I real-time PCR assay.

M. Magnani, C. Gori, F. Forbici, 2007, Molecular and cellular probes.

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients

A. Antinori, C. Perno, C. Gori, 2014, Journal of the International AIDS Society.

The Effect of Number of Mutations and of Drug-Class Sparing on Virological Response to Salvage Genotype-Guided Antiretroviral Therapy

P. Narciso, A. Antinori, V. Tozzi, 2002, Antiviral therapy.

Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy

F. Ceccherini‐Silberstein, O. Turriziani, A. Antinori, 2019, Sexually Transmitted Infections.

No significant association between patient self-reported non-adherence to antiretrovirals and HIV-tropism: a preliminary analysis

M. Capobianchi, P. Lorenzini, C. Perno, 2012, Journal of the International AIDS Society.

The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2016, Journal of global antimicrobial resistance.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

F. Ceccherini‐Silberstein, E. Nicastri, C. Perno, 2015, The Journal of antimicrobial chemotherapy.

Virologic Correlates of Adherence to Antiretroviral Medications and Therapeutic Failure

F. Ceccherini‐Silberstein, V. Vullo, A. Antinori, 2002, Journal of acquired immune deficiency syndromes.

Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2019, Antiviral therapy.

gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure.

A. Antinori, R. Bellagamba, M. Ciccozzi, 2007, AIDS Research and Human Retroviruses.

Virological response and resistance profile in HIV‐1‐infected patients starting darunavir‐containing regimens

F. Ceccherini‐Silberstein, E. Nicastri, C. Mussini, 2017, HIV medicine.

Dynamics and phylogenetic relationships of HIV-1 transmitted drug resistance according to subtype in Italy over the years 2000–14

A. Mariano, F. Ceccherini‐Silberstein, V. Vullo, 2017, The Journal of antimicrobial chemotherapy.

Drug-Class-Wide Resistance to Antiretrovirals in HIV-Infected Patients Failing Therapy: Prevalence, Risk Factors and Virological Outcome

P. Narciso, A. Antinori, V. Tozzi, 2005, Antiviral therapy.

Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2006, The new microbiologica.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

F. Ceccherini‐Silberstein, P. Narciso, M. Capobianchi, 2011, The Journal of antimicrobial chemotherapy.

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.

F. Ceccherini‐Silberstein, P. Narciso, C. Perno, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

The lowest X 4 Geno 2 Pheno false-positive rate is associated with greater CD 4 depletion in HIV-1 infected patients

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012 .

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Subtype analysis and mutations to antiviral drugs in HIV‐1‐infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM programme

L. Palombi, C. Perno, M. Marazzi, 2005, Journal of medical virology.

Historical resistance profile helps to predict salvage failure

Francesca Ceccherini-Silberstein, F. Ceccherini‐Silberstein, P. Narciso, 2009, Antiviral therapy.

Genetic divergence of HIV-1 B subtype in Italy over the years 2003–2016 and impact on CTL escape prevalence

F. Ceccherini‐Silberstein, A. Antinori, R. Bellagamba, 2018, Scientific Reports.

Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs

L. Pucillo, A. Antinori, C. Perno, 2014, BMC Medical Genetics.

Historical resistance profile helps to predict salvage failure

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2009, Antiviral therapy.

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.

Domenico Di Carlo, F. Ceccherini‐Silberstein, M. Andreoni, 2015, The Journal of antimicrobial chemotherapy.

Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen.

A. d’Arminio Monforte, F. Ceccherini‐Silberstein, K. Theys, 2013, The Journal of antimicrobial chemotherapy.

Effect of Suppressing HIV Viremia on the HIV Progression of Patients Undergoing a Genotype Resistance Test after Treatment Failure

F. Ceccherini‐Silberstein, P. Narciso, V. Tozzi, 2009, Infection.